Excessive Sedation With Depot Zyprexa Can Be Handled In Label, Cmte. Says
Executive Summary
Labeling that restricts use and a risk management plan for the depot formulation of Lilly's Zyprexa (olanzapine) will be enough to balance the risk of excessive sedation associated with the atypical antipsychotic, according to FDA's Psychopharmacologic Drugs Advisory Committee